Lenacapavir as pre-exposure prophylaxis for HIV prevention. [PDF]
Ebrahim S +8 more
europepmc +1 more source
Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir. [PDF]
Niu J +9 more
europepmc +1 more source
Virologic Outcomes With Lenacapavir in People With Human Immunodeficiency Virus: A Multicenter Real-World Study. [PDF]
Kaperak C +14 more
europepmc +1 more source
Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP? [PDF]
D'Angelo AB +3 more
europepmc +1 more source
CA Inhibitor 1 Treatment Does Not Affect Estrous Cyclicity in Mice. [PDF]
Giacometti LL +5 more
europepmc +1 more source
Beyond Efficacy: The Access, Delivery Systems, Acceptability, Persistence, and Transition Management "ADAPT" Framework for Long-Acting Injectable PrEP in Sub-Saharan Africa. [PDF]
Ikoona EN +4 more
europepmc +1 more source
Challenges facing long-acting PrEP implementation in large populations. [PDF]
Sun C, Liao Y.
europepmc +1 more source
Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa. [PDF]
Phillips A +15 more
europepmc +1 more source
Long-Acting Antiretroviral Therapy for HIV via Drop-in Community-Based Care.
Mehtani NJ +9 more
europepmc +1 more source
HIV capsid inhibitors: Mechanisms, resistance, and therapeutic advances. [PDF]
Mahdi M +4 more
europepmc +1 more source

